SOUTH SAN FRANCISCO, Calif & CAPE TOWN, South Africa--(BUSINESS WIRE)--Titan Pharmaceuticals, Inc. (AMEX:TTP) today presented detailed data from its positive Phase 3 placebo controlled study of Probuphine in the treatment of opioid addiction. Titan also presented new data from an ongoing open-label Phase 3 trial of Probuphine. Probuphine is a novel, subcutaneous implant formulation of buprenorphine using Titan’s ProNeura™ technology to deliver six months of medication after a single administration. These findings were presented today at the 2008 annual meeting for the International Society of Addiction Medicine (ISAM) Congress which began on November 16, 2008 and continues through November 20, 2008 in Cape Town, South Africa.
